RxDoctor Payments Data

Amy Akridge

Family · Jefferson City, TNNPI 1407469919

Payments from drug & device makers

$4,184in general payments, 2019–2025

Across 204 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$685
  • Johnson & Johnson$302
  • Novartis$291
  • Pfizer$238
  • Lilly USA, LLC$229
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,10498%
  • Education$802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,184 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$49,436
Medicare patients
268
Services billed
1,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab163$1,182,470
Enbrel SureclickEtanercept112$845,208
RinvoqUpadacitinib99$660,651
Orencia ClickjectAbatacept107$631,582
Enbrel MiniEtanercept47$355,488
Cosentyx Sensoready PenSecukinumab39$338,944
Xeljanz XrTofacitinib Citrate25$157,057
OtezlaApremilast33$144,313
RemicadeInfliximab14$138,317
XeljanzTofacitinib Citrate24$137,910
EnbrelEtanercept17$128,216
Humira(Cf)Adalimumab17$118,907
Cosentyx Sensoready (2 Pens)Secukinumab15$115,517
BenlystaBelimumab17$100,862
Hydroxychloroquine Sulfate1,373$45,051

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$1,203$779,558116 claims
AmgenOtezla, Enbrel$685$272,52950 claims
Johnson & JohnsonRemicade$302$138,31714 claims
PfizerXeljanz$238$137,91024 claims
GSKBenlysta$21$100,86217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.

Other family in Jefferson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →